The Novacyt share price has crashed: here’s what I’d do now

The Novacyt share price fell by 40% on Friday. Roland Head looks at the outlook for the Covid-19 testing specialist and explains what he’s doing now.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

Shares in medical testing specialist Novacyt (LSE: NCTY) fell by 40% on Friday. Its share price crashed after the company said it had failed to agree a contract extension to supply Covid-19 tests for the NHS in 2021.

To make matters worse, the company’s now also in dispute with the NHS over sales during the final quarter of 2020.

Novacyt’s share price opened at around 430p on Monday morning. That values the business at just two times 2020 forecast earnings. That’s an unusually low valuation for a profitable business.

This former high flyer is now worth 15% less than it was a year ago. Should I buy Novacyt for my portfolio today — or is this business a one-hit wonder that’s past its peak?

What we know

Sales to the NHS generated 50% of revenue during the first quarter of this year. But Novacyt has failed to secure a contract extension with this important customer. Management now says sales and profits are likely to be lower than expected this year.

And with Novacyt in a legal dispute with the NHS relating to those final quarter 2020 sales, I don’t know what the financial impact of this might be. But it’s probably not good news.

There’s a stock market saying that profit warnings often come in threes. Although that’s not always true, in my experience a company’s first profit warning is often followed by further bad news. If this happens, I think Novacyt’s share price could have further to fall.

What happens next?

It was always obvious that demand for Covid-19 testing would start to fall at some point. But the firm’s comments on Friday suggest to me that demand may already be slowing.

The main testing product Novacyt sells to the NHS is called PROmate. According to management, PROmate sales during the first quarter “may be sufficient” to satisfy NHS demand “for the remainder of 2021.”

The company hopes to continue selling PROmate to private sector clients and international markets. But if NHS demand is falling, then I’d guess demand elsewhere might fall too.

The company’s aim is to use its success during the pandemic to build a wider portfolio of testing and diagnostic products. So far, we haven’t heard much about this. But Novacyt ended last year with a cash balance of €101m, so it should have the funding it needs to develop new products and make acquisitions.

Novacyt share price: my decision

It’s worth remembering that until last year, Novacyt’s annual sales had peaked at €14m and the firm had never made a profit. Covid-19 testing proved to be a bonanza for the group, which secured valuable NHS contracts and generated sales of €312m in 2020.

Before last Friday, 2020 profits were expected to be €185m. With a market-cap of £345m and net cash of €101m, Novacyt shares look cheap to me on a historical view.

However, investment is about the future. And that looks pretty uncertain to me. In my view, buying the shares today means betting that CEO Graham Mullis can secure new business to replace Covid-19 testing.

I don’t know how likely this is. But my gut feeling is that it’ll be difficult to do quickly. I won’t be buying Novacyt shares just yet.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Santa Clara offices of NVIDIA
Investing Articles

The Nvidia share price hit an all-time high this week. But could it still be a bargain?

The Nvidia share price has soared 1,466% in just five years. This writer reckons the best may yet be to…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

How much does someone need to invest to target a second income of £15k – or £150k?

A second income from dividend shares? It's a well-worn path -- and this writer sees some attractions to the approach.…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

Could the stock market crash in the second half of 2025?

As the FTSE 100 hits a new high, could a stock market crash be coming? Our writer thinks there's a…

Read more »

Man hanging in the balance over a log at seaside in Scotland
Investing Articles

Start investing this summer with a spare £250? Here’s how!

Christopher Ruane explains how an investor with a few hundred pounds to spare and no prior experience could look to…

Read more »

Young female analyst working at her desk in the office
Investing Articles

Is Palantir stock the new Nvidia? Why UK investors should (or shouldn’t) care

Palantir stock’s the top performer on the S&P 500 this year. Should UK investors consider it amid a blistering AI-fuelled…

Read more »

Investing Articles

3 FTSE 100 shares I think look undervalued

The FTSE 100 may be hitting record highs but there are still bargains to be had on the index. I…

Read more »

Close-up image depicting a woman in her 70s taking British bank notes from her colourful leather wallet.
Investing Articles

£20,000 in savings? Here’s how to target £841 of passive income each month

Passive income plans don't need to be complicated. Our writer explains how someone could target a sizeable second income buying…

Read more »

Happy couple showing relief at news
Investing Articles

3 passive income strategies I like to try to double the State Pension with just £100 a month

Investing consistently, with diligence, and patience can lead to an impressive stock market income that puts the State Pension to…

Read more »